Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2023 17:29 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Pricing of $7 Million Public Offering

BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...
June 06, 2023 16:01 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Glioblastoma

BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat...
May 22, 2023 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces 1-for-20 Reverse Stock Split

BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA...
April 27, 2023 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial

BOSTON, April 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to...
April 26, 2023 08:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary platform delivery system to...
April 14, 2023 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Equity Investment from White Lion Capital to Help Fund Development of TTX-MC138 for Treatment of Glioblastomas

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using...
April 06, 2023 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics to present at AACR Annual Meeting 2023

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today...
April 05, 2023 07:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138

BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today...
April 04, 2023 21:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Termination of Previously Announced Sale of Series A Preferred Stock

BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology CompanyTM committed to more effectively treating cancer using RNA therapeutics, today...
April 03, 2023 08:00 ET | Source: TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Agreement with Triton Funds for Sale of Series A Convertible Preferred Stock

BOSTON, April 03, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right